US 12,377,067 B2
Methods of treating PAH with combinations of ralinepag and other agents
Dominic P. Behan, San Diego, CA (US); John W. Adams, San Diego, CA (US); and Lucie H. Clapp, London (GB)
Assigned to ARENA PHARMACEUTICALS, INC., San Diego, CA (US); and Lucie H. Clapp, London (GB)
Appl. No. 16/348,665
Filed by Arena Pharmaceuticals, Inc., San Diego, CA (US); and Lucie H. Clapp, London (GB)
PCT Filed Nov. 10, 2017, PCT No. PCT/US2017/061116
§ 371(c)(1), (2) Date May 9, 2019,
PCT Pub. No. WO2018/089804, PCT Pub. Date May 17, 2018.
Claims priority of provisional application 62/420,515, filed on Nov. 10, 2016.
Claims priority of provisional application 62/530,533, filed on Jul. 10, 2017.
Prior Publication US 2019/0321328 A1, Oct. 24, 2019
Int. Cl. A61K 31/32 (2006.01); A61K 31/192 (2006.01); A61K 31/325 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 9/12 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/325 (2013.01) [A61K 31/192 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); A61P 9/12 (2018.01); A61P 35/00 (2018.01)] 32 Claims
 
1. A method of treating pulmonary arterial hypertension in a human, comprising administering to the human with pulmonary arterial hypertension a therapeutically effective amount of ralinepag, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in combination with a therapeutically effective amount of riociguat.